On November 21, 2025, the DOJ announced that Dr. Ameet Vohra and his company, Vohra Wound Physicians Management, one of the nation's largest providers of specialty wound care for patients in nursing homes and skilled nursing facilities, have agreed to pay $45 million to resolve allegations that they submitted false and improper claims to Medicare.
The case began in April 2025, when the United States filed a civil lawsuit under the False Claims Act against Vohra and related entities, formally accusing them of a nationwide scheme to defraud Medicare using a systemic program of upcoding and false documentation—converting non-surgical or routine wound care (or care not provided at all) into high-paying surgical billings, repeatedly and across the country.
For a complex nationwide False Claims Act case, this matter settled in record time, just over seven months after the complaint was filed, suggesting regulators are accelerating enforcement in this space.
The Alleged Scheme
According to the DOJ's complaint:
In addition to paying $45 million, Dr. Vohra and Vohra Wound Physicians Management will also enter into a five-year Corporate Integrity Agreement with HHS-OIG. Under the agreement, Vohra must implement and maintain a compliance program, conduct risk assessments, and hire an independent review organization to monitor their claims and health-information technology systems.
Wound Care Fraud is An Enforcement Priority
The Vohra settlement is not an outlier but instead part of a larger trend. Over the past few years, federal authorities have repeatedly targeted wound-care providers, skin graft/supplement suppliers, and other entities that treat chronic wounds. In January 2025, federal prosecutors announced that an Arizona couple had pleaded guilty for orchestrating a huge fraud scheme in which they submitted over $1.2 billion in false and fraudulent claims to Medicare and other federal insurance programs for medically unnecessary skin grafts on elderly and terminally ill patients.
In April 2023, HHS-OIG excluded Dr. Joel Aronowitz and Tower Multi-Specialty Medical Group from Medicare for 15 years—and forced them to pay nearly $24M—for allegedly submitting improperly billed claims for skin substitute products.
A recent report by HHS-OIG provides helpful context for what might be fueling this alarming pattern. The report found that Medicare Part B spending on skin substitutes soared in 2023–2024—rising to over $10 billion in 2024, up roughly 640% from just two years earlier. The aggressive enforcement and the dramatic growth in skin substitute billing make it clear that wound care and skin grafts are now among the top targets for enforcement under the False Claims Act.
Listen to Mary Inman and Monitor Mondays host, Chuck Buck, discuss the settlement in the latest episode of the Monitor Monday Podcast. The attorneys at Whistleblower Partners have extensive experience representing whistleblowers in cases involving healthcare fraud. If you would like more information or wish to speak to an attorney at Whistleblower Partners, please contact us for a confidential consultation.